Valneva Overview
- Founded
-
1999

- Status
-
Public
- Employees
-
628

- Stock Symbol
-
VLA

- Investments
-
4
- Share Price
-
$6.79
- (As of Wednesday Closing)
Valneva General Information
Description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
Contact Information
- 6, Rue Alain Bombard
- 44800 Saint-Herblain
- France
Valneva Timeline
Valneva Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.79 | $6.78 | $4.81 - $20.61 | $940M | 138M | 358K | $0.91 |
Valneva Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 389,763 | 2,651,647 | 814,142 | 279,305 |
Revenue | 571,418 | 411,540 | 125,756 | 141,269 |
EBITDA | 103,378 | (46,068) | (51,163) | 11,302 |
Net Income | 79,451 | (86,810) | (73,402) | (1,952) |
Total Assets | 686,137 | 925,423 | 552,457 | 296,535 |
Total Debt | 158,853 | 129,815 | 129,701 | 95,457 |
Valneva Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Valneva Comparisons
Industry
Financing
Details
Valneva Competitors (80)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CureVac | Formerly VC-backed | Tubingen, Germany | 0000 | 00.000 | 00000000 | 00.000 |
0000000 | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
0000000 | Corporation | Beijing, China | 0000 | 00000 | 000000 - 000 | 00000 |
000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
0000000 0000000000 | Corporation | Emeryville, CA | 000 | 00000 | 000000000 | 00000 |
Valneva Patents
Valneva Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3174666-A1 | Improved methods of producing a lipidated protein | Pending | 09-Apr-2020 | 000000000 | |
CA-3174599-A1 | Improvements in vaccine formulations for medical use | Pending | 09-Apr-2020 | 000000000 | |
AU-2021253605-A1 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | 000000000 | |
CA-3168784-A1 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | 000000000 | |
EP-3955959-A2 | Inactivated sars-cov-2 virus vaccine | Pending | 06-Apr-2020 | A61K39/12 |
Valneva Executive Team (15)
Valneva Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Alain Munoz Ph.D | Self | Scientific Advisory Board Member | 000 0000 |
Anne-Marie Graffin | Valneva | Supervisory Board Member | 000 0000 |
Anne-Marie Graffin | Self | Board Member | 000 0000 |
Frederic Grimaud | Valneva | Chairman & Board Member | 000 0000 |
James Sulat | Self | Board Member & Vice Chairman | 000 0000 |
Valneva Signals
Valneva Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Valneva Investments & Acquisitions (4)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 09-Feb-2015 | 0000000000 | 000.00 | Biotechnology | 000000 00 |
00000 0000000 | 11-Dec-2014 | 00000 0000 | 00.000 | Biotechnology | 000000 00 |
000000000 | 16-Dec-2012 | 000000 00 | Biotechnology | ||
Humalys | 01-Jan-2010 | Merger/Acquisition | 000.00 | Biotechnology |
Valneva ESG
Risk Overview
Risk Rating
Updated January, 14, 2023
29.03 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Biotechnology
Subindustry
00 of 465
Rank
Percentile
